Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Lithium & Battery Tech ETF (LIT) vs Zoetis Inc (ZTS) Price & Performance

Global X Lithium & Battery Tech ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Global X Lithium & Battery Tech ETF vs Zoetis Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.25, while Zoetis Inc trades at $74.93 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while Global X Lithium & Battery Tech ETF pays none, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

LITZTS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$91.62$156.76
52-Week Low
$40.80$71.91
Market Cap
$31.95B
Enterprise Value
$39.24B
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Lithium & Battery Tech ETF

LIT trades at $66.92, down 2.14% on the day, reflecting recent volatility amid shifting EV market dynamics. The ETF has doubled over the past year, driven by strong momentum in lithium, energy storage, and semiconductor sectors. Key holdings benefit from global EV sales growth, with June marking the fourth consecutive monthly increase. A dividend of $0.32 is scheduled for July 2026, providing income potential.

Outlook remains positive due to structural demand for lithium in EVs and renewables, though risks include Chinese export controls and U.S.-China trade tensions. Analyst sentiment is bullish, citing inflection in lithium markets and reshoring trends. Investors should monitor policy developments and supply chain stability for sustained gains.

Zoetis Inc

Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.

The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Lithium & Battery Tech ETF

LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.

Read more on LIT

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS